49results about "Polypeptide with Strep-tag" patented technology

The invention relates to mutant forms of CsgG. The invention also related to analyte detection and characterisation using CsgG.

The present invention relates to modified Dda helicases which can be used to control the movement of analytes such as polynucleotides. The modified Dda helicases are used in analyte detection and characterisation. The present invention also relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore.

The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.

To provide a system including novel nanopores having different structures and recognition sites that improve sequencing accuracy and / or provide different error profiles.SOLUTION: Provided are systems relating to the field of nanopores and their use in various applications, e.g., analysis of biopolymers and macromolecules, typically by making electrical measurements during translocation through the nanopore, comprising a funnel-shaped proteinaceous nanopore comprising alpha-helical pore-forming toxins that are members from the actinoporin family of proteins, more particularly Fraga Ceatoxin C (FraC), a variant FraC, a FraC paralog or a FraC homolog.SELECTED DRAWING: None

Provided are a single-chain polypeptide which is highly activated after entering a specific use site, attenuated and can be safer and more convenient to produce, and the corresponding use thereof, a nucleic acid encoding same and a preparation method therefor. The single-chain polypeptide comprises: a first domain, an intermediate amino acid sequence region, and a second domain, wherein the intermediate amino acid sequence region is located between the first domain and the second domain, and contains at least one first enzyme cleavage site, the first enzyme cleavage site is designed to be capable of being highly specifically cleaved by a first protease present in a specific part of the human body, and the single-chain polypeptide is converted into an activated form capable of inhibiting the release of an information substance after being cleaved by the first protease at the first enzyme cleavage site.

The present invention provides a combination comprising a) an antigen binding domain specific for CD90, and b) an antigen binding domain specific for CD326, for use in treatment of human cancer comprising cancerous cells that co-express CD90 and CD326. In one embodiment of the invention the combination comprises a) an immune cell comprising a CAR comprising an antigen binding domain specific for a tag of a first and a second polypeptide, b) said tagged first polypeptide that has an antigen binding domain specific for CD90, and c) said tagged second polypeptide that has an antigen binding domain specific for CD326, wherein the tag of the first polypeptide and the tag of the second polypeptide are identical. In a further embodiment the concentrations used for said first and that second polypeptide are below the activation threshold of said CAR, respectively, but the sum of both concentrations is above the activation threshold of said CAR.

The invention relates to a method for identifying and quantifying a polypeptide from a library of polypeptides. The method comprises the steps of: 1 - providing a polypeptide library and a detection tag library, 2 - generating a nested library comprising the polypeptides and the detection tags, 3 - sequencing the nested library, 4 - selecting a member of the nested library in one or several selection steps that are independent of a physical genotype-phenotype linkage, 5 - isolating the detection tag from the selected polypeptide, 6 - identifying and quantifying the detection tag by mass spectrometry, 7 - obtaining the sequence of the selected polypeptide.

The invention discloses a method for promoting yarrowia lipolytica to synthesize carotenoid, which comprises the following steps of: recombining and expressing beta-carotene hydroxylase CrtZ and / or beta-carotene ketolase CrtW fused with a short peptide label in the yarrowia lipolytica producing beta-carotene; site-specific mutagenesis is carried out on the amino acid site of CrtZ; and a CrtZ coding gene is integrated in a multi-copy manner. The invention also discloses a yarrowia lipolytica genetically engineered bacterium for producing beta-carotene, wherein carotenoid is selected from zeaxanthin, canthaxanthin and astaxanthin. The yield of zeaxanthin, canthaxanthin and astaxanthin in yarrowia lipolytica is remarkably increased through enzyme label engineering, combinatorial optimization and site-specific mutagenesis strategies, and a new path is provided for efficient synthesis of carotenoids.

The present invention relates to modified Dda helicases that can be used to control the movement of analytes, such as polynucleotides. The modified Dda helicases are used in the detection and characterization of analytes. The present invention also relates to novel protein pores and their use in the detection and characterization of analytes. The present invention particularly relates to isolated pore complexes formed by CsgG-like pores and modified CsgF peptides, or homologs or variants thereof, thereby incorporating an additional channel constriction or reader head within the nanopore.

The present invention relates to mutant forms of the outer membrane-located lipoprotein CsgG, in particular modifications at one or more of positions Tyr51, Asn55 and Phe56. The invention also relates to the use of said mutant CsgG for analyte detection and characterization.

Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin. Such antibodies are useful in methods of treatment for diseases mediated by alternative complement pathway dysregulation.

The presently disclosed subject matter provides compositions and systems for cell-based immunotherapy. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and at least one soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide.

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Described herein are polypeptides and nanoparticles that display polypeptide sequences, e.g., spike protein domains. In some embodiments, the polypeptides and / or nanoparticles can be used to raise or stimulate an immune response, e.g., as a vaccine.

The present invention relates to an isolated polypeptide having amino acylase activity and comprising an amino acid sequence having at least 87% sequence identity over its full length to the amino acid sequence set forth in SEQ ID NO: 1. The invention further relates to isolated nucleic acid molecules comprising a nucleotide sequence encoding such an aminoacylase, plasmid vectors comprising said nucleic acid molecules, recombinant host cells comprising isolated nucleic acid molecules or vectors, and methods of producing said aminoacylase. The invention also encompasses the use of an aminoacylase according to the invention for the N-acylation of an amino acid or a salt thereof, as well as a method for producing an N-acylamino acid or a salt thereof using an aminoacylase. Furthermore, the present invention relates to the N-acylamino acids obtained, to compositions comprising them, and to the use of the N-acylamino acids produced in cosmetics, home care products or industrial and / or institutional products.

To provide compositions and methods for the in vivo synthesis of non-natural polypeptides containing non-natural amino acids.SOLUTION: Disclosed herein are compositions, methods and kits for cells that incorporate unnatural amino acids into unnatural polypeptides. Also disclosed herein are compositions, methods and kits for increasing the activity and yield of non-naturally occurring polypeptides synthesized by a cell.SELECTED DRAWING: None

The application discloses an E2 fusion protein, a coding gene thereof and application of the E2 fusion protein. The E2 fusion protein is fused by an E2 protein and a label; the amino acid sequence of the E2 protein is shown as positions 1 to 365 from the N-terminal end in SEQ ID NO:1. Experiments prove that the E2 protein has a helicase activity, and an anti-human papillomavirus drug, a podophyllotoxin, can inhibit the helicase activity of the E2 protein. Therefore, the E2 protein is a target of the action of the podophyllotoxin, and the E2 protein can also be used as a target for screening the anti-human papillomavirus drug. The application has important application value in the process of screening the anti-human papillomavirus drug.

A method is described for the rapid clearance of carbon monoxide (CO) from CO-bound hemoglobin, myoglobin, and cytochrome c oxidase in subjects with CO poisoning. The disclosed therapeutic method involves the use of rationally designed and engineered regulator of CO metabolism (RcoM) proteins and pharmaceutical compositions thereof, which scavenge CO from poisoned tissues. The recombinant RcoM composition is infused into the blood, where it rapidly sequesters CO and limits the toxic effects of CO on cellular respiration, oxygen transport, and oxygen utilization.

The present invention relates to a nanoparticle, comprising an assembly of bacterial encapsulin protein monomers, and a protein located inside the nanoparticle, wherein the protein is a dimer or tandem-enzyme wherein each enzyme of the dimer or tandem is fused to at least one terminal targeting peptide (TP). The invention further relates to nanoparticles comprising modified encapsulin proteins, and methods and uses of the nanoparticles in medicine, industry, cleaning and biotechnology.

The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.

The present invention relates to mutant forms of the outer membrane-located lipoprotein CsgG, in particular modifications at one or more of positions Tyr51, Asn55 and Phe56. The invention also relates to the use of said mutant CsgG for analyte detection and characterization.

The present invention relates to a gene construct characterized by encoding a fusion protein of flgM and Strep-tag through the linkage of an anti-sigma factor flgM gene and a gene encoding Strep-tag, enabling the expression of Strep-tag on the surface of an anti-cancer strain that can target tumor sites and stimulate immune activity, and to an anti-cancer adjuvant and tumor imaging agent that, when transformed by this construct, exhibits anti-cancer activity itself and can be effectively utilized in the diagnosis and treatment of tumor cells together with anti-cancer substances or contrast agents labeled with substances specifically interacting with Strep-tag.

Provided herein are methods for preparing and characterizing SARS-cov2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections, and immune disorders. Also provided are compositions and methods for generating immune calls expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARS-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

Described herein are isolated monovalent antibodies or antibody fragments thereof that bind human properdin. Such antibodies are useful in methods of treatment for diseases mediated by alternative complement pathway dysregulation.

Provided herein are compositions and methods for preparing a purified population of single chain Mycobacterium smegmatis porins.

The application discloses a kind of compositions for detecting NAD + And application thereof, and relates to the field of biological detection.The application discloses a kind of compositions for detecting NAD + The composition comprises: NAD + Binding protein fragment A connected with Fc label, NAD + Binding protein fragment B and connecting peptide, and its detection result is accurate and reliable, simultaneously avoids the technical difficulty, uncertainty and high cost faced in screening antibody in traditional method.

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

The present invention relates to an isolated polypeptide having aminoacylase activity and comprising an amino acid sequence having over its entire length at least 87 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 1. The invention further relates to an isolated nucleic acid molecule comprising a nucleotide sequence encoding such an aminoacylase, to a plasmid vector comprising said nucleic acid molecule, to a recombinant host cell comprising the isolated nucleic acid molecule or the vector and to methods to produce said aminoacylase. The invention also covers the use of the aminoacylase according to the invention for the N-acylation of amino acids or salts thereof as well as methods to produce N-acyl amino acids or salts thereof using the aminoacylase. Furthermore, the invention relates to the obtained N-acyl amino acids, compositions comprising them and the use of the produced N-acyl amino acids in a cosmetic product, home care product or an industrial and / or institutional product.

Provided herein are compositions and methods for functionalizing a polypeptide for single-molecule analysis. In some aspects, the disclosure provides compositions and methods for immobilizing a peptide barcode to a surface. In some aspects, the disclosure provides compositions and methods for luminescently labeling a protein of interest.